<b>添付文書からみた承認時と再審査終了時における副作用発現率の比較</b>

  • 渡邉 達也
    北里大学大学院薬学研究科臨床医学(医薬開発学) 北里大学北里研究所病院バイオメディカルリサーチセンター
  • 岩崎 麻美
    北里大学大学院薬学研究科臨床医学(医薬開発学)
  • 氏原 淳
    北里大学北里研究所病院バイオメディカルリサーチセンター
  • 成川 衛
    北里大学大学院薬学研究科臨床医学(医薬開発学)

書誌事項

タイトル別名
  • <b>Comparison of Adverse Drug Reaction Rates in the Package Insert at the Time of New Drug Approval and at Re-Examination</b>
  • Comparison of Adverse Drug Reaction Rates in the Package Insert at the Time of New Drug Approval and at Re-Examination
公開日
2013
DOI
  • 10.3999/jscpt.44.463
公開者
一般社団法人 日本臨床薬理学会

この論文をさがす

説明

Among various sources of information on ethical drugs, many medical personnel refer to the “package insert” in many occasions because of its reliability and availability. Every new drug is subject to “re-examination” usually after 8 years of marketing approval, in which its efficacy and safety are reexamined based on data obtained from post-marketing studies and others. The package insert is usually revised based on the result of re-examination and the revised insert contains information on adverse drug reactions reported both in clinical trials for marketing approval and post-marketing studies. Therefore the revision may be considered to be a major milestone, which provides a general idea of the safety profile of a new drug at marketing approval as well as after being on the market. In the present study, we compared adverse drug reaction rates at the time of new drug approval and at re-examination based on the revised package inserts to which safety information from postmarketing studies was added. The result showed that the rate of adverse drug reactions at re-examination had decreased compared to that at marketing approval for most of the new drugs investigated. In recent years, more and more new drugs are approved with less domestic clinical trial data. Therefore, pharmacists, as specialists on pharmaceuticals, are expected to understand correctly and provide safety information on pharmaceuticals based on proper understanding of the background of new drug development and not solely confined to the figures in the package inserts.<br>(Jpn J Clin Pharmacol Ther 2013; 44(6): 463-468)

収録刊行物

  • 臨床薬理

    臨床薬理 44 (6), 463-468, 2013

    一般社団法人 日本臨床薬理学会

被引用文献 (2)*注記

もっと見る

参考文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ